Next, survival analysis was conducted in the Kaplan–Meier Plotter website and showed that increased expression of MAPK4 was associated with unfavorable overall survival (OS) and progression-free survival (PFS) of NSCLC patients (Fig. S5I, J). Here, MAPK4 is linked to non-small cell lung carcinoma.